Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13910104 | 0.82 | L3MBTL1 (0.38) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL10149375 | 0.77 | CA1 (0.45) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL10211551 | 0.77 | CA1 (0.57) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL9790160 | 0.77 | CA1 (0.57) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL10061696 | 0.77 | CA1 (0.57) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL11949313 | 0.75 | CA1 (0.55) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL11949314 | 0.75 | CA1 (0.55) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL13654286 | 0.75 | CA1 (0.55) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL13654289 | 0.75 | CA1 (0.55) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL30528703 | 0.74 | CA1 (0.54) | CA1CA2CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834035-B2 | Schizophrenia and related disorders; positive allosteric modulators of mGluR5; {3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone for example; compounds are all contain a 5-(1-carbonylpiperidin-3-yl)-1,2,4-oxadiazole moiety | ADDEX PHARMA SA (CH) | 2010-11-16 | — | — | US | disclosed |
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM1 | CA1 2771/4885CA2 1869/4885CA12 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.